BofA analyst Craig Siegenthaler raised the firm’s price target on CME Group (CME) to $200 from $190 and keeps an Underperform rating on the shares after the company reported adjusted EPS of $2.52, with the 3% beat primarily driven by several non-operating items. Following the report, the firm raised its 2025, 2026 and 2027 EPS estimates to $10.55, $10.98, and $11.41, respectively, to embed higher non-operating income going forward as well as better-than-expected guidance for pricing and expenses.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CME:
- CME Group price target raised to $263 from $256 at Morgan Stanley
- CME Group price target raised to $257 from $256 at Keefe Bruyette
- CME Group Inc. Reports Record Year and Positive Outlook
- CME Group price target raised to $269 from $235 at RBC Capital
- CME Group price target raised to $263 from $257 at Barclays
Questions or Comments about the article? Write to editor@tipranks.com